Numerous diseases result from damaged cells and tissues in the body. Healthy pluripotent stem cells could be used to replace these. RHEINCELL produces such therapeutic stem cells while avoiding immune rejections.

RHEINCELL THERAPEUTICS GmbH specializes in the GMP-compliant generation of human induced pluripotent stem cells (iPS cells) from so-called HLA-homozygous cord blood units. Our focus is on setting up an iPS master cell bank under GMP conditions. This master cell bank will serve as a key production platform for the „on-demand“ generation of various cell therapeutics, such as retinal pigment epithelial cells for the treatment of age-related macular degeneration.

Our expertise covers the entire spectrum of the medically oriented iPSC workflow and is based on our long-standing expertise in human iPSC technology. This includes cellular reprogramming under GMP conditions, GMP/ATMP-grade iPSC expansion and cryopreservation, targeted genetic manipulation (optional) and directed differentiation.

This website uses cookies to provide the best possible functionality. Find out more in our privacy policy.